Sut mae Llywodraeth Cymru yn sicrhau bod digon o gapasiti yn y ganolfan driniaeth genedlaethol CAR-T?
Wedi'i ateb gan Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol | Wedi'i ateb ar 04/07/2023
I recognise the importance of access to Advanced Therapeutic Medicinal Products (ATMPs) such as Chimeric Antigen Receptor T-cell (CAR-T) therapy.
The Welsh Health Specialised Services Committee is responsible for commissioning this service on behalf of health boards in Wales.
The Committee is working with its commissioned providers to deliver the required level of capacity in response to increased patient demand and new recommended indications.
Cardiff and Vale University Health Board is developing a business case for its future provision of bone marrow transplant and CAR-T therapy.